PDCD1 and non-small cell lung carcinoma: Recent clinical studies in the immunotherapy of PD-1/PD-L1 showed positive significant responses for many advanced cancers such as gastric and gastro-oesophageal junction adenocarcinomas, non-small cell lung cancer, and malignant melanoma [64,65,66].